# VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

> **NCT03603808** · PHASE2 · COMPLETED · sponsor: **AIDS Malignancy Consortium** · enrollment: 44 (actual)

## Conditions studied

- Anal Intraepithelial Neoplasia
- High Grade Squamous Intraepithelial Neoplasia
- HIV Positivity
- Human Papillomavirus-16 Positive
- Human Papillomavirus-18 Positive

## Interventions

- **DEVICE:** Electroporation
- **BIOLOGICAL:** HPV DNA Plasmids Therapeutic Vaccine VGX-3100
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT03603808
- **Lead sponsor:** AIDS Malignancy Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-21
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-06-17
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2026-05-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03603808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03603808, "VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions". Retrieved via AI Analytics 2026-06-21 from https://api.ai-analytics.org/clinical/NCT03603808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*